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ABSTRACT Next-generation DNA sequencing (NGS) has progressed enormously over the past decade, transforming genomic
analysis and opening up many new opportunities for applications in clinical microbiology laboratories. The impact of NGS on
microbiology has been revolutionary, with new microbial genomic sequences being generated daily, leading to the development
of large databases of genomes and gene sequences. The ability to analyze microbial communities without culturing organisms
has created the ever-growing field of metagenomics and microbiome analysis and has generated significant new insights into the
relation between host and microbe. The medical literature contains many examples of how this new technology can be used for
infectious disease diagnostics and pathogen analysis. The implementation of NGS in medical practice has been a slow process
due to various challenges such as clinical trials, lack of applicable regulatory guidelines, and the adaptation of the technology to
the clinical environment. In April 2015, the American Academy of Microbiology (AAM) convened a colloquium to begin to define these issues, and in this document, we present some of the concepts that were generated from these discussions.

U

se of next-generation DNA sequencing (NGS) (Table 1) in
infectious disease diagnostics has progressed slowly over the
past 10 years despite continued advances in sequencing technology. The first commercial NGS platform, the GS20 sequencer
from 454 Life Sciences, which was originally released in 2005 (1,
2), resulted in a more than 100-fold increase in the amount of
microbial genomic sequence data produced in a day compared to
preceding instruments. Despite the growing body of literature and
research broadly applying sequencing-based technology to disease
pathophysiology, epidemiology, and clinical diagnostics, the clinical microbiology laboratory has yet to widely adopt NGS technology. As microbiology laboratories are faced with a wealth of innovative and often costly molecular technologies, the role of NGS in
clinical infectious disease diagnostics needs to be carefully evaluated.
A number of highly publicized case reports and clinical studies
have showcased the application of NGS as a single diagnostic tool
with the potential to be broadly applicable to infectious disease
diagnostics. Metagenomic (Table 1) sequencing has demonstrated its ability to identify microbial pathogens where traditional
diagnostics have otherwise failed. For example, it is estimated that
63% of encephalitis cases go undiagnosed despite extensive testing
(3). Several cases in the literature have successfully employed NGS
to diagnose rare, novel, or atypical infectious etiologies for encephalitis, including cases of infection by Leptospira (4), astrovirus
(5), and bornavirus (6). In one case, 38 different diagnostic tests
had been conducted and failed to yield an actionable answer before a single NGS assay was performed, which identified the
pathogen (4). Similarly, the utilization of metagenomic NGS
identified divergent astrovirus clades in a pair of patients with
encephalitis and demonstrated the unusual zoonotic potential of a
group of these viruses (7).
Another promising application of NGS technology is hospital
infection control surveillance programs and community outbreak
investigations (8). By conducting whole-genome sequencing
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(WGS) (Table 1), organisms can be identified at the subspecies/
strain level based on the single nucleotide polymorphisms (SNPs)
(Table 1) and other variants (Table 1) in their genotype. WGS
through NGS technology offers greater precision than do moretraditional typing tools such as multilocus sequence typing and
pulsed-field gel electrophoresis, which may assist in refining outbreak investigations and better guide infection control interventions (9). Because WGS analysis requires significant amounts of
sequencing data, traditional sequencing methods preclude the use
of WGS analysis for outbreak investigations. However, NGS platforms can generate the large volume of data needed for SNP or
variant analysis and have led to a rapid expansion in the use of
WGS for public health investigations. For example, WGS using
NGS technology was applied to investigate an outbreak of
hemolytic-uremic syndrome caused by an unusual strain of Escherichia coli in Germany (10), the origins of the 2010 Haitian Vibrio
cholerae epidemic (11), a series of methicillin-resistant Staphylococcus aureus infections in a neonatal intensive care unit (12), and
the origins of a series of nosocomial carbapenem-resistant Klebsiella pneumoniae infections (13), among many others.
While identification of causative microorganisms of disease is
the chief responsibility of clinical microbiology laboratories, conducting antimicrobial resistance testing to guide therapy is among
the most important tests conducted in the laboratory. NGS has the
potential to suggest antimicrobial resistance through identificaPublished 8 December 2015
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TABLE 1 Glossary of terms used in DNA sequence analysis
Term

Abbreviation

16S rRNA gene

Alignment

Assembly

Contig

Dideoxynucleotide sequencing
Metagenomics
Metagenomic whole-genome
shotgun sequencing

mWGS

Microbiome

Next-generation sequencing

NGS

Reference genome

Read

Sanger sequencing

Single nucleotide polymorphism

SNP

Variant

Whole-genome shotgun sequencing
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WGS

Definition
A slowly evolving gene in bacteria whose sequence
is used for definition of taxa. It is a gene that is
targeted for sequencing in microbiome analysis,
where the goal is enumeration of the taxa
present in a community.
The process of comparing the sequence of a single
sequencing read or a contig/whole genome
following assembly to a reference genome.
The goal is often to identify the organism
from which a sequencing read came or to
identify variants within the sequence.
Reconstructing a genome, in whole or in part,
from the fragment sequences produced
by WGS (or mWGS).
A contiguous stretch of sequence produced when
a series of overlapping sequence reads are
merged to produce a single longer sequence.
A “classical” method of DNA sequencing that preceded
NGS and is frequently called Sanger sequencing.
Analyzing a mixture of microbial genomes, a metagenome,
without separating the genomes or culturing the organisms.
The application of WGS to a metagenomics sample. DNA
is extracted from the sample, producing a
mixture of genomes, which are then subjected
to WGS en masse.
A community of microbes comprising bacteria, viruses,
and fungi and other eukaryotic microbes. Often
the target of metagenomic analyses.
A collection of DNA sequencing methods that each
use different biochemical approaches and instruments
to produce data in vastly larger amounts, at greatly
lower cost, in shorter time, and with less manual
intervention than previous methods.
A genome sequence of a particular organism that can
be used as a standard, e.g., for alignment or
comparison of other genomes.
The basic element produced by DNA sequencing.
Sequencing of a DNA fragment produces a
series of bases called a sequencing read.
A “classical” method of DNA sequencing that preceded
NGS but was almost exclusively used from the
1970s until the advent of NGS. Compared to
NGS, it produced fewer data, was more
expensive, and required more manual work.
A difference of a single base compared to a reference
genome. These can be substitutions of one
base for another or insertion/deletion
of a base (indel).
Any difference in a DNA sequence compared to
a reference sequence. This can be a single-base
difference (SNP) or insertions, deletions,
inversions, or translocations of larger
stretches of sequence (structural variants).
Randomly fragmenting an entire genome and obtaining
DNA sequence from the fragments to produce
a collection of random DNA sequences. This
can be applied to a single bacterium or to a
mixture (metagenomc; see mWGS). These
data can be used to identify variants following
alignment of genes by comparison to sequence
databases or to compare genome structures
following assembly.

November/December 2015 Volume 6 Issue 6 e01888-15

Downloaded from mbio.asm.org on January 14, 2016 - Published by mbio.asm.org

Minireview

tion of known resistance genes (14). Although WGS is in the early
stages of development, studies have suggested that WGS can be
used to predict antibiotic resistance with performance characteristics approaching those of traditional phenotypic testing. Stoesser
et al. (15) demonstrated sensitivity and specificity of 96% and
97%, respectively, when using WGS to predict antibiotic resistance for clinical isolates of E. coli and K. pneumoniae. Comparative genomic sequencing has also been used to identify daptomycin resistance due to point mutations in metabolic genes that
occurred during therapy for two cases of vancomycin-resistant
enterococcal bacteremia which were ultimately fatal (16, 17). Earlier application of WGS might have detected these point mutations and guided therapy. However, it has not been established if
WGS can be broadly applied to the full spectrum of pathogenic
bacteria, particularly those with a diverse armamentarium of resistance mechanisms. WGS analysis of antimicrobial resistance
genes could be particularly beneficial for slow-growing or
difficult-to-culture organisms and organisms that elude phenotypic testing altogether. The use of WGS is not limited to the
detection of bacterial resistance genes. WGS has also been applied
for the following purposes: detection of low-level drug resistance
among human immunodeficiency virus (HIV) “escape” variant
populations (e.g., protease inhibitor [PI] and reverse transcriptase
minor sequence variants) and coreceptor tropism (CCR5 and
CXCR4) and analyses that are not possible using current genotypic and phenotypic HIV assays (18). These successes and potential applications of WGS analysis have been made possible by the
advance of NGS technology, which provides the tools to produce
useful WGS data.
Metagenomic shotgun sequencing (mWGS) (Table 1) is often
used to study microbial communities in human disease in order to
identify correlative or causative relations. Such communities
comprise hundreds of different taxa of bacteria, viruses, and fungi
and other eukaryotic microbes. Many of these organisms are difficult to culture, and culture-independent methods of performing
comprehensive sampling of these complex communities have
been the major obstacle to analysis. NGS is currently the best
available analytical approach to profile microbiomes (Table 1) for
this purpose. To date, NGS has helped elucidate the role of the
lung and gut microbiomes in both general health and various
diseases, including obesity, inflammatory bowel disease, cystic fibrosis (CF), metabolic syndrome, type II diabetes, and cardiovascular disease (19–23). As NGS continues to expand our knowledge
base on metagenomics, microbiome analysis may produce diagnostic or prognostic biomarkers to guide therapeutic decisions.
There is a long-standing precedent in clinical microbiology
laboratories to adopt new technology that complements or supplants existing “gold standard” testing. The viral culture bench is
all but extinct in most clinical laboratories, with PCR-based molecular assays currently dominating viral diagnostics. Nonviral
microbial diagnostics have been relatively slow to adopt molecular
technology, but this is rapidly changing with a new generation of
molecular diagnostics that utilize specific PCR primers for different bacterial, parasitic, and fungal targets. Several of these multiplex assays have already received U.S. Food and Drug Administration (FDA) clearance and offer laboratories an attractive and easy
way to detect clinically relevant microbial pathogens. Similarly to
the impact of PCR technology, microbial NGS diagnostics offer
another step forward in the quality and quantity of information
that could potentially be provided to clinicians and patients. In
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April 2015, the American Academy of Microbiology (AAM) conducted a colloquium to critically evaluate the trends in the use of
NGS for infectious disease diagnostics. Below, we describe some of
the concepts that evolved from the AAM’s NGS colloquium (report to be published).
NEXT-GENERATION SEQUENCING

DNA sequencing technology was previously dominated by procedures using the dideoxynucleotide chain termination method
(also referred to as Sanger sequencing) (Table 1) for close to
30 years. In the mid-2000s, a number of new methods began to
appear, commonly referred to as the “next-generation sequencing
methods.” The first method that was widely commercialized was
the “pyrosequencing” method—a method that formed the basis
for the 454 Life Sciences instruments for about 10 years until the
company closed in 2015. These instruments had a major impact
on microbial genomics and became the leading platform for producing whole-genome sequences from individual bacteria as well
as the platform of choice for sequencing 16S rRNA (Table 1) genes
in microbiome analyses.
Since the advent of NGS, there has been an ongoing expansion
of sequencing methods and instruments as well as continual improvements in the quality, quantity, and cost of sequences that are
produced. The spectrum of common and available instruments
current as of July 2015 is shown in Table 2, which indicates the
considerable range in characteristics of NGS options.
An understanding of how these characteristics match the various NGS applications is useful to appreciate the strengths or limitations of different sequencing approaches. To sequence a single
microbial genome, the genome is fragmented into manageablesize pieces, which are then used in WGS (Fig. 1). Depending on the
sequencing platform, this can produce sequences (i.e., reads) (Table 1) that range from hundreds of bases to thousands or tens of
thousands of bases in length. When the goal is to produce a microbial genome, the reads are assembled into a single genome
sequence using a variety of computational strategies. Often, the
assembly (Table 1) leaves gaps, and the individual chunks of
genomic sequence that result are called contigs (Table 1). When
identifying variants in the genome (e.g., for typing or tracking),
the reads are directly aligned with a reference genome (Table 1)
where the sequence variants are determined. The smaller the
length of sequence read, the more contigs and gaps that are produced during the assembly process. Hence, there is a preference
for longer sequence reads. To obtain a complete sequence without
gaps, one often uses both short and long reads to combine the
strengths of these various sequencing approaches (24). However,
the platforms producing shorter reads are often less expensive and
can yield large amounts of data. Moreover, the accuracy of base
calls comprising the sequence read is also important. The lower
the accuracy of the read, the more reads (i.e., coverage) that are
required to obtain good contigs, ultimately driving up the sequencing costs. In addition, when reads have errors, it is harder to
identify the true sequence variants. At present, platforms that produce longer reads tend to have lower accuracy and users have to
consider the tradeoffs between the various platforms when designing a project.
Another major application for NGS is metagenomic sequencing. In this case, one starts with a particular specimen type such as
stool, saliva, a nasal swab, etc., with the goal of determining the
bacteria, viruses, fungi, and other microbes that are present. Fol-
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TABLE 2 Current spectrum of popular, available NGS instruments (as of July 2015)a
Read length
(accuracy)

No. of
reads/run

Run time

Run cost ($)

No. of genomes/
metagenomes per run

Comment

ⱕ300 bases
(high up to
250 bases)
ⱕ150 bases (high)
ⱕ250 bases (high)

ⱕ20 million

ⱕ2.5 days

ⱕ1,500

40/4

Read pairs

ⱕ400 million
ⱕ300 million

ⱕ1.2 days
2.5 days

ⱕ5,000
⬍8,000

400/60
300/80

~10 kb (low
for single pass)

70,000

ⱕ4 h

ⱕ1,200

3/TBD

LT Ion PGM

ⱕ400 bases

ⱕ5 million

ⱕ7 h

ⱕ750

7/1

LT Ion Proton

ⱕ200 bases

ⱕ80 million

ⱕ4 h

1,000

30/16

ONT MinION

10 kb–100 kb (low)

Variable

Variable

1,000

TBD

Read pairs
Read pairs,
rapid run mode
Shorter (e.g., 2-kb)
reads have higher
quality; no
paired ends
PGM318 chip;
no paired ends
PI chip; no
paired ends
No paired ends;
beta testing

Instrument
ILMN MiSeq

ILMN NextSeq
ILMN
HiSeq 2500
PB RSII

a Abbreviations: ILMN, Illumina; LT, Life Technologies; PB, Pacific Biosciences; ONT, Oxford Nanopore Technologies. TBD, to be determined. ILMN is from Illumina. LT is from
http://allseq.com/knowledgebank/sequencing-platforms/life-technologies-ion-torrent. Genomes/run, 100⫻ coverage of a 3-Mb genome. Metagenomes/run, 5 million reads
(pairs)/metagenome.

lowing DNA extraction, a series of processing and bioinformatics
steps are performed to produce NGS data for analysis (Fig. 2),
analogous to the whole-genome sequence of an individual microbe described above; however, in this case the method is applied
to a mixture/community of microbes. While the genomic se-

FIG 1 NGS genome analysis. The general process of using NGS for analysis of
a single genome is depicted in this figure. Note that there are many variations
on this approach. Purified DNA (i.e., input genome) is fragmented and run
through the DNA sequencing process. The sequencing instrument produces
either short (e.g., for Illumina) or long (e.g., for Pacific Biosciences) sequence
reads depending on the platform used. When the goal is to produce a complete
genome (e.g., for identifying virulence or antibiotic resistance genes or for
comparative genomic studies), the reads are assembled into genomes using
specialized software. Some gaps in the assembly may occur, leading to a draft
genome sequence composed of many contigs. When the genome is assembled
without gaps, it is said to be closed. When the goal is to identify variants (e.g.,
SNPs) with respect to a reference genome, the reads can be aligned directly
with the reference genome and sequence variants can be identified using specialized programs. These variants serve to define the organism at the subspecies and strain level and are useful in epidemiological tracking as well as to
identify mutations that occur.

4
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quences produced can be assembled, because of the various abundances of organisms, there is often not enough sequence from
rarer organisms to produce a complete genome, and assembly
results in very short contigs for these genomes in the mixture.
More commonly, the sequence reads are aligned against databases
of many (typically thousands) genome sequences to identify the
likely source organism for the sequence. The abundance of such
source organisms is estimated from the number of reads that
match their genomes. In this way, one can identify and estimate
the abundance of organisms that are present in the original patient
sample.
The high throughput of NGS allows data to be produced from
many individual bacteria/samples in a single sequencing run of
hours to days. This is a vast improvement over the early days of
bacterial sequencing when a single bacterial genome project could
take years. Likewise, because a metagenomic sample is complex
and contains hundreds of taxa at abundances ranging over many
orders of magnitude, previously it was not possible to accurately
assess the community structure by culture-based methods or traditional Sanger sequencing, which could handle only cultivable
organisms or hundreds of sequences at best. With the availability
of NGS, it is now possible to obtain millions or more of sequences
per run, thus enabling deep sampling and more descriptive analysis of the microbial community on a truly useful level.
CLINICAL APPLICATIONS

The potential clinical applications of NGS are vast and engage
clinical microbiology at every level of the development process,
such as outbreak tracking across the country, hospital infection
control surveillance, pathogen discovery, mutation detection in a
specific isolate, identification of multiple pathogens in a single
sample, identification of viral quasispecies, and individual host
response to infection (Fig. 3). These tests are poised to revolutionize infectious disease diagnostics and the practice of clinical microbiology. Initial reports of NGS applications for clinical diagnostics first appeared more than 5 years ago; however, the
technology has not yet entered routine use within clinical micro-
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FIG 2 NGS workflow. A high-level overview of the steps taken in the NGS data production process and some of the equipment and software used in this process.
The specific instruments and programs may vary as there are multiple solutions (e.g., Table 2). DB, database; QA, quality assurance; seq’ing, sequencing; conc,
concentration; LIMS, laboratory information management system.

biology laboratories. Reports continue to appear in the medical
literature of individual case studies or small-scale applications of
NGS to clinical microbiology, but experience remains limited.
The technology itself is still hobbled by the enormous amount of
basic research and resources needed to transform this technology
into a robust clinical application for infectious disease diagnostics.
To date, the medical community is still awaiting large-scale clinical trials to establish the utility of NGS in different clinical settings;
however, comprehensive funding and incentives for these studies
are limited.
Although NGS has the potential to provide a huge volume of
information to health care practitioners with respect to both microbial characteristics and the host response to disease, it will be
necessary to determine strategies to pragmatically deal with this
data barrage. Many of the potential applications to clinical medicine are not known. In the field of bacteriology, NGS has particular limitations in determining which organisms are merely “innocent bystanders” or are colonizers rather than active pathogens.
For instance, a potentially pathogenic microorganism identified
from one specimen type, such as cerebrospinal fluid (CSF) or
synovial fluids, which are typically thought to be sterile, may be
normal in the skin, gut, or mouth.
The potential implications for physicians/practitioners, and
particularly antimicrobial stewardship, are staggering. One important question: if currently a certain percentage of practitioners
treat patients with antibiotics even when lacking evidence of a
bacterial pathogen, what will they do when presented with a
pathogen that is likely (but not absolutely) a contaminant?
More importantly, a paradigm shift in the understanding of
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molecular diagnostics will be necessary for clinicians and professionals in the clinical microbiology community. Both molecular
diagnostics and traditional culture-based technology have their
strengths and weaknesses. One of the strengths of NGS assays is
the ability to detect many microorganisms directly from a patient
sample without needing additional testing or a priori knowledge
of the type of pathogen. NGS can potentially detect viruses, bacteria, yeast, fungi, and parasites without the need for additional
individual testing. However, both traditional technologies and
NGS assays have limitations in detection that can be clearly defined. But while culture absolutely indicates the presence of living
organisms, the presence of organismal DNA is less definitive.
Ultimately, clinical studies and eventually clinical trials examining patient outcomes will be necessary to reinforce the cost savings and benefit of using NGS-based clinical tests for the diagnosis
of infectious disease. A prominent issue with such studies is the
scarcity of funding. Because of how expensive these analyses are to
conduct, they can be unattractive to industry and require a certain
amount of patience and determination from the clinical community to perform correctly and in an economically wise manner.
Moreover, such studies require establishing fundamentals such as
standard operating procedures for NGS diagnostics. At present,
there is no standardization between studies, much less between
different institutions. All aspects of the NGS diagnostic pipeline
remain variable, including clinical specimen collection, sequencing parameters, data analysis/interpretation, and data reporting.
Such details must be established before clinical outcomes can be
systematically examined.
Determining the optimal approach to advance the use of NGS
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the near future. Additional clinical studies are needed to explore
the capabilities of NGS assays for these applications and the potential partnership between NGS and culture-based assays.
As NGS technology continues to mature, the research and
medical communities will need to establish the analytical performance of each assay, the clinical validity for different pathogens,
and, most importantly, the clinical niche for NGS. The shift to
molecular diagnostics will require a change in the thinking of clinicians and clinical microbiology professionals. Upcoming generations of physicians, clinical providers, and clinical microbiologists will need to adjust to the strengths and limitations of these
new tools. Like any new powerful technology, molecular diagnostics pose challenges in data interpretation and reporting but could
more quickly and completely diagnose infection and provide critical information for clinical management. Despite all of the potential limitations and hurdles to the clinical applications of NGS
assays, they present a remarkable opportunity to advance the field
of clinical microbiology.
REGULATORY CONSIDERATIONS

FIG 3 Potential clinical applications for metagenomics sequencing. There are
numerous potential applications of NGS technology to the clinical microbiology laboratory. Each entry in the chart represents a potential area for the
utilization of NGS diagnostics and/or future research.

poses serious challenges. For example, how would a clinical laboratory determine the analytical validation of a device that could
potentially pick up any known or novel pathogens? While the
majority of clinical infections are typically attributed to a finite
number of bacterial, viral, and fungal pathogens, a main attraction
of NGS for clinical diagnosis is the ability to capture rare or unsuspected, yet potentially actionable, pathogens. It is tremendously appealing to identify both pathogen and patient genomic
sequence information for everything from virulence genes to
strain-level sequence variants to an assessment of the patient response to infection or effectiveness of antibiotic therapy. The advancement of NGS technology into pathogen genomics could potentially provide supplemental descriptive or predictive
information regarding the potential antimicrobial resistance gene
profile of the microorganism and allow for more rapid selection of
appropriate antimicrobial therapy. Although early studies have
reported promising results for antimicrobial resistance detection,
the most valuable piece of antimicrobial resistance information is
the antimicrobials to which the organism is susceptible (15, 25),
and it is unclear what the strength of NGS for predicting susceptibility as opposed to resistance will be. Additionally, as bacteria
and viruses are constantly evolving new resistance mechanisms,
reference databases would have to be continuously updated to
include novel resistance genes and mutations in order for NGS to
be an effective predictor. Thus, it seems unlikely that the clinical
laboratory will be moving away from phenotypic confirmation in
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The imminent adaptation of NGS-based infectious disease diagnostics in the clinical microbiology laboratory poses significant
regulatory challenges for U.S. device developers and manufacturers. The technology itself is still evolving, and there is a need for
new development of guidelines and streamlining of insurance reimbursement codes for the use of NGS testing in clinical microbiology laboratories. While the test is going through the approval
process, an upgrade or new instrument will likely appear on the
market that can perform that same test with a shorter turnaround
time and at a lower cost. However, constant technology improvement is not unique to clinical microbial NGS. This is one of the
current obstacles where resources are scarce to develop validated
tests while demand for this novel technology is rising. As mentioned in the introduction, various publications showcase situations in which microbial NGS-based tests guided or improved
diagnostic and therapeutic decisions. Such decisions cannot be
made with current laboratory diagnostic devices.
Infectious disease NGS-based diagnostic devices are in vitro
diagnostic (IVD) tests intended for use in the diagnosis of diseases
or other conditions, including infections. Some tests are used in
laboratory or other health professional settings, and other tests are
intended for use by a patient to collect samples at home. IVDs are
medical devices as defined in section 210(h) of the U.S. Federal
Food, Drug, and Cosmetic Act and may also be biological products subject to section 351 of the Public Health Service Act. Similarly to other medical devices, IVDs are subject to premarket and
postmarket controls. IVDs are also subject to the Clinical Laboratory Improvement Amendment of 1988 (CLIA ‘88) (26). In the
United States, clinical diagnostic tests have to make an appropriate premarket submission and obtain approval or clearance for
their test from the FDA prior to marketing. Sequence-based clinical diagnostic devices for the microbiology laboratory are raising
new policy and regulatory issues; thoughts presented here are preliminary and do not represent finalized FDA policy. The FDA
encourages submitters to contact the FDA, using the presubmission program to discuss the premarket submission strategy for
their specific test (27).
During FDA’s Microbial Sequencing workshop held on 1 April
2014, scientific and clinical community leaders emphasized the
benefits of regulatory oversight of infectious disease NGS-based

November/December 2015 Volume 6 Issue 6 e01888-15

Downloaded from mbio.asm.org on January 14, 2016 - Published by mbio.asm.org

Minireview

FIG 4 The FDA is considering the following information for the clearance/approval of an infectious disease NGS-based test/assay. The FDA presubmission
process can be utilized for outstanding questions and to request additional information while policy is still being developed (26). IRB, institutional review board.

diagnostic devices due to challenges that these devices pose for
patient management (28). The following challenges were identified at the workshop: (i) the absolute need for immediate and
actionable results, (ii) the broad range of specimen types (e.g.,
urine, blood, CSF, stool, sputum, and others), (iii) the broad diversity of the infectious disease agents possibly present within a
single specimen, and (iv) the dynamic nature of infectious disease
agents. The request from scientific and clinical community leaders
for guidance on infectious disease sequencing parallels the challenges faced by matrix-assisted laser desorption ionization
(MALDI)–time of flight (TOF) mass spectrometry diagnostics
prior to their widespread integration into the clinical microbiology laboratory.
Moreover, the publications referenced in the introduction and
input from stakeholders at FDA’s Microbial Sequencing workshop outlined that detection and identification of infectious disease organisms and antimicrobial resistance or virulence markers
have progressed from culture-based methods to molecular methods using nucleic acid amplification and hybridization technologies. Today, single-approach high-throughput techniques or NGS
may potentially replace previous methods which required several
different tests. An infectious disease NGS diagnostic device differs
from traditional devices that target specific organisms or virulence/resistance markers by being able to simultaneously detect
every organism present in a sample during a single run. These
challenges call for a novel regulatory approach tailored to the specific NGS technology and microbiology application used in the
diagnostic assay. To date, the only in vitro diagnostic NGS system
(i.e., assay and instrument) to have obtained FDA marketing au-
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thorization is the Illumina MiSeqDx system. This authorization
marks a significant milestone for NGS technology (29). The Illumina MiSeqDx system is tailored for the detection of cystic fibrosis
(CF) (i.e., cystic fibrosis carrier screening for the general population and detection of the CF gene for CF patients); the Illumina
MiSeqDx system has not been cleared by the FDA for microbial
diagnostic use. Currently, the FDA is developing concepts for validation of NGS tests for infectious disease diagnostics and the
detection of antimicrobial resistance and virulence markers. The
FDA is also working on introducing models for streamlining clinical trials for the validation of infectious disease NGS diagnostic
tests and other sequence-based microbial molecular diagnostics.
Quality metrics and metadata parameters for microbial genomic
sequence entries are currently being developed for use in regulatory decisions.
Since policy and regulatory issues for these devices are still
evolving, the FDA presubmission process is a helpful tool for developers to inquire about specific information on studies required
for evaluation of NGS-based devices. These studies are aimed at
elucidating how NGS technologies can aid in infectious disease
diagnostics and at gaining a better understanding of potential
NGS clinical implementation strategies. The purpose of the presubmission program is to give a submitter an opportunity to discuss specific questions with the FDA regarding product development or application preparation. The FDA review of
presubmission protocols leads to better-prepared submissions.
Through the presubmission process, input can be given on possible approaches to validation studies and data for the evaluation of
infectious disease NGS-based diagnostics (Fig. 4). The FDA can
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provide guidance on the available regulatory pathways and assistance on how to evaluate performance using sequence outputs
from infectious disease NGS-based devices. Quality metrics for
reference databases are among the most critical validation issues
as discussed by stakeholders during the FDA Microbial Sequencing workshop. Efforts toward generating an initial set of highquality, regulatory-grade microbial genomic reference sequences
through the FDA-ARGOS project in collaboration with various
federal agencies are under way. The FDA’s vision is a public, highquality, regulatory-grade microbial reference database that contains qualified sequence data for use by developers and clinical end
users.
As with other molecular biology-based diagnostic devices,
FDA is considering using a “one-system” approach for the evaluation of infectious disease NGS diagnostic devices—from sample
collection through the output of clinically actionable data. The
components of the system generally include a specimen collection
device, instruments, reagents, software (if applicable) used to generate the sequencing library or otherwise prepare the specimen for
sequencing, the sequencing instruments along with the associated
reagents and data collection elements that generate the raw sequence reads, and the data analysis pipeline (i.e., assembly, annotation, and variant calling, as applicable). Further, the FDA is considering using methods from the discipline of systems science to
evaluate these devices. This approach will evaluate, in parallel, the
“system” as a whole, from specimen collection to the individual
steps in the sequencing data pipeline to the generation of clinically
actionable data.
FDA-ARGOS. The FDA, in collaboration with various federal
agencies, has developed the database entitled FDA-ARGOS (FDA
database for regulatory-grade microbial sequences; BioProject
231221). To promote a least-burdensome regulatory approach for
devices that incorporate infectious disease NGS diagnostic technology, the FDA considers the use of an alternative comparator
method for clinical evaluation that relies heavily on public databases populated with regulatory-grade target genomic reference
sequences. This database supplies a set of validated regulatorygrade microbial genomic sequence entries which is available at the
National Center for Biotechnology Information (NCBI) website.
Regulatory-grade microbial sequences are near-complete highquality draft genomes with metadata requirements (30).
In order to advance from proof of concept to implementation
of NGS-based diagnostics in U.S. clinical laboratories and hospitals, assays must undergo standardization, optimization, validation, and, eventually, automation. Once each step of the workflow
has been optimized for efficiency, overall functionality and performance characteristics must be determined for the entire test.
Validation requires the calculation of analytical sensitivity and
specificity, accuracy, precision, and limit of detection (31). The
National Institute for Standards and Technology (NIST) is developing whole-genome microbial reference standards to support
the validation process for genomic sequencing-based diagnostic
assays (32). Four microbial species that are clinically significant
and vary in genome characteristics (e.g., size, GC content, and
presence of accessory elements) are being characterized by NIST
through evaluating genome assembly, base-level analysis,
genomic purity, and genomic stability (33). These reference materials can be used during appropriate steps to support validation
of a microbial NGS-based diagnostic assay. NGS is a multistep
technology for which validation has to occur among all levels of
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“wet” and “dry” processes described above. Guidance for developing specific protocols and quality control procedures that assess
NGS tests is needed. For example, metrics should be established
for the number of individual sequence reads that must match a
genomic reference sequence or marker for a particular organism
(32, 34). To aid in validating the bioinformatics or “dry” components of NGS, attendees at the AAM’s colloquium suggested an in
silico, characterized data set that could be downloaded and run
through the clinical laboratory’s bioinformatic pipeline. It may
be necessary for a group of regulatory agencies such as the FDA,
the Centers for Medicare and Medicaid Services (CMS), the
National Institutes of Health (NIH), the Centers for Disease
Control and Prevention (CDC), and the College of American
Pathologists (CAP) to collaborate on the formulation of guidelines for the validation of infectious disease NGS-based diagnostic assays.
Another regulatory challenge that encompasses the transition
of NGS into the clinical microbiology laboratory is management
of patient data. Because microbial NGS data are generated from a
patient’s clinical sample, storage of the genomic information must
be secure and uphold Health Insurance Portability and Accountability Act (HIPAA) regulations. Offsite remote cloud processing
and data storage have become a popular alternative to local bioinformatics infrastructure, although no regulatory legislation is in
place for these online tasks. It is well known that an established
bioinformatics workflow, including storage and retrieval facilities
for microbial genome sequence analyses, requires a substantial
financial investment which may not be available or feasible for
many clinical microbiology laboratories. Raw sequence reads consume considerable storage space, and thus, it was suggested at the
colloquium to deposit raw data in the Short Read Archive (SRA) at
the NCBI and the assembled/annotated genome in a central repository (35). It was also highly recommended by colloquium
attendees to document only the clinically actionable result and
analysis parameters in the patient’s medical record, thereby decreasing the data footprint cost.
Not only do microbial genomic data hold immense value for
the clinical microbiology field, but their power could be leveraged
to help the public health and scientific research communities
through implementation of open data sharing practices. Many
discussions at the AAM’s colloquium focused on the need for a
publicly available, unified, genomic reference database that is filtered with metadata and maintains patient confidentiality and privacy laws. A centralized database with a continuous stream of new
microbial genomes could serve as a vital resource (35, 36). It was
suggested that guidelines for responsible data sharing and transfer
be created by a group of relevant stakeholders to assist in maximizing public availability of microbial genomic data and to limit
the creation of private genome sequence databases. Incorporation
of new data repositories could occur with established databases
such as the multiorganizational effort known as the International
Nucleotide Sequence Database Collaboration (INSDC), an initiative that endorses data sharing among three existing databases:
NCBI, European Nucleotide Archive (ENA), and DNA Data Bank
of Japan (DDBJ). To truly understand the benefits that NGS diagnostic assays could have for the broader clinical microbiology
community, data sharing through a constantly evolving, centralized reference repository is essential.
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CONCLUSION

Despite the enormously attractive potential of NGS for infectious
disease diagnosis, there are many challenging, time-consuming,
and costly bridges to cross before this technology can become
mainstream and part of the clinical standard of care. However, the
clinical literature has demonstrated that this technology can be
successfully applied to solve medical diagnostic dilemmas and be
likely useful for clinical cases that fail or challenge the limits of
traditional laboratory testing. Although many potential impediments to the utilization of NGS-based diagnostics exist, it would
be a loss to the medical community if this technology could not be
applied to patient care in some capacity. The burden is on the
infectious disease and genomics communities to bring these tools
to the world of clinical diagnostics and to keep pace with the ongoing evolution of the analytical and computational aspects of
NGS. Ten years ago, it would have been inconceivable that a single
human genome could be sequenced in a day and for less than
$1,000. Yet, today the clinical microbiology laboratory is facing
the same scenario, and one cannot fully envision all other infectious disease applications that will be possible in the near future.
The rapid evolution of NGS challenges both the regulatory framework and the development of laboratory standards and will require additional funding and incentives to drive tangible improvements and progress. Cooperation among the medical and research
communities, industry, regulatory bodies, and professional societies will help to develop innovative solutions to these challenges
and to realize the potential benefit that NGS has for patients and
their families.
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